Nuvation Bio Q4 Revenue Estimated at $37.33M, One-Year Target Suggests 105% Upside
Nuvation Bio is forecast to report Q4 2025 revenue of $37.33 million and a loss of $0.09 per share when it releases earnings on March 2, 2026, boosting full-year 2025 revenue estimates to $58.80 million. Analysts’ average one-year price target of $11.90 implies 105% upside from $5.80.
1. Q4 2025 Earnings Preview
Nuvation Bio will report Q4 2025 results on March 2, 2026, with revenue forecast at $37.33 million and a loss of $0.09 per share, reflecting expectations of ongoing investment in its clinical portfolio.
2. Estimate Revisions
Over the past 90 days, full-year 2025 revenue estimates rose from $54.77 million to $58.80 million, while EPS loss forecasts narrowed from $0.60 to $0.59 per share; 2026 revenue projections climbed from $163.16 million to $174.38 million with EPS losses improving from $0.51 to $0.49.
3. Analyst Price Targets and Upside
Based on one-year targets from 10 analysts, the average price target is $11.90, with a range of $10.00 to $17.00, implying roughly 105% upside versus the current $5.80 share price and an Outperform consensus rating.
4. Recent Quarter Outperformance
In Q3 2025, revenue reached $13.12 million, beating the $6.61 million consensus by 98.4%, and a $0.16 per share loss outpaced the $0.17 estimate by 5.3%, though shares declined over 6% in the session following the release.